314241-04-8

Basic information

• Product Name: 2-fluoro-4-(Methoxycarbonyl)benzoic acid
• Synonyms: 2-fluoro-4-(Methoxycarbonyl)benzoic acid
• CAS NO: 314241-04-8
• Molecular Formula: C9H7FO4
• Molecular Weight: 198.1478832
• Mol File: 314241-04-8.mol
• Article Data: 7

Chemical Properties

• Melting Point: 154-155 °C(Solv: ethyl acetate (141-78-6))
• Boiling Point: 335.5±32.0 °C(Predicted)
• Appearance: /
• Density: 1.375±0.06 g/cm3(Predicted)
• PKA: 2.84±0.10(Predicted)
• CAS DataBase Reference: 2-fluoro-4-(Methoxycarbonyl)benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-fluoro-4-(Methoxycarbonyl)benzoic acid(314241-04-8)
• EPA Substance Registry System: 2-fluoro-4-(Methoxycarbonyl)benzoic acid(314241-04-8)

Safety Data

• Hazardous Substances Data: 314241-04-8(Hazardous Substances Data)

Usage

Description

2-fluoro-4-(Methoxycarbonyl)benzoic acid is an organic compound characterized by the presence of a fluorine atom at the 2nd position and a methoxycarbonyl group at the 4th position on a benzoic acid backbone. This molecule exhibits unique chemical properties due to the presence of the fluorine atom, which can influence its reactivity and interaction with other molecules.

Uses

Used in Pharmaceutical Industry:
2-fluoro-4-(Methoxycarbonyl)benzoic acid is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure and reactivity make it a valuable building block for the development of new drugs with potential therapeutic applications.
Used in the Preparation of Retinoid X Receptor Antagonists:
2-fluoro-4-(Methoxycarbonyl)benzoic acid is used as a reagent in the preparation of diazepinylbenzoic acid, which is a retinoid X receptor antagonist. These antagonists play a crucial role in modulating the activity of the retinoid X receptor, a nuclear receptor that is involved in various physiological processes, including lipid metabolism, cell differentiation, and inflammation. By targeting this receptor, diazepinylbenzoic acid and its derivatives may have potential applications in treating conditions related to these processes, such as metabolic disorders and inflammatory diseases.

Upstream product

• 193290-80-1 3-fluoro-4-formylbenzoic acid 
• 777074-51-8 4-(dibromomethyl)-3-fluorobenzoic acid 
• 350-28-7 3-fluoro-4-methyl-benzoic acid 
• 87808-48-8 methyl 3-fluoro-4-methylbenzoate 
• 74733-25-8 methyl 3-fluoro-4-formylbenzoate 
• 5292-47-7 1,4-dimethyl 2-fluorobenzene-1,4-dicarboxylate 

Downstream Products

• 1190848-21-5 3-fluoro-4-((3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbonyl)benzoic acid 
• 1190848-44-2 methyl 3-fluoro-4-((3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbonyl)benzoate 

Relevant articles and documents

A practical synthesis of a diazepinylbenzoic acid, a retinoid X receptor antagonist

An optimized convergent synthetic route for the preparation of retinoid X receptor (RXR) antagonist (1) in an overall yield of 35% is described. The formation of the benzodiazepine was achieved in 85% yield using POCl3 in toluene. The drug subs

Diaryl 2- amide-substituted thiophene imide ester compound as well as preparation method and application thereof (by machine translation)

The invention also discloses a 2 - synthesis method thereof, and an application of the compound as an antibacterial agent, in the phthisis-caused by the bacterium, in particular to the, mycobacterium-induced infectious disease (especially (Tuberculosis,TB), mycobacterium- induced mycobacterium, tuberculosis), and (I) the invention, specifically relates to a pharmaceutical composition containing the compound of the present invention or, a R pharmaceutical composition comprising the compound of the present invention. 1 , R2 , R3 , R4 , R5 As described Y in the present invention. as described in the specification, the present invention is directed, to the preparation of novel compounds, having an anti-mycobacterial activity as potential, new drug (s) for the treatment (TB) or preventative treatment of infectious diseases, consisting of M. tuberculosis, in particular phthisis- caused by tubercular mycobacteria, while being useful in overcoming the problems associated with drug resistance. (by machine translation)

Synthesis and structure-activity relationship of novel RXR antagonists: Orally active anti-diabetic and anti-obesity agents

A series of diazepinylbenzoic acid derivatives were synthesized and tested in the inhibition assay of the transactivation of RXR. Oral treatment of cyano derivatives (16f) was found to show anti-diabetic and anti-obesity effects in KK-Ay mice.